Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
June 13 2024 - 7:00AM
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a
clinical-stage biopharmaceutical company focused on delivering
groundbreaking therapies using its lipid nanocrystal (LNC) platform
delivery technology, announces that MAT2203, its oral formulation
of the potent antifungal amphotericin B, will be featured in a
fireside chat with David S. Perlin, PhD, a recognized expert in
antifungals. The event is being sponsored by Alliance Global
Partners (A.G.P.) and hosted by Scott Henry, A.G.P. Managing
Director and Senior Research Analyst.
Topics of discussion will include an overview of
the antifungal market and current treatment options, the clinical
potential of MAT2203 as an oral formulation of amphotericin B, the
market potential of MAT2203 and the design and key factors in the
MAT2203 ORALTO pivotal trial in patients with invasive
aspergillosis who have limited treatment options.
|
Event: |
Fireside Chat
with Dr. David Perlin |
|
Date: |
June 18, 2024 |
|
Time: |
4:00 p.m. Eastern time |
|
Registration: |
Participants can register to attend the event here. An archived
webcast will be available for 60 days. |
|
|
|
Participants will have the opportunity to ask
questions through the event platform.
Dr. David Perlin is the
inaugural Chief Scientific Officer and Executive Vice President for
the Hackensack Meridian Center for Discovery and Innovation, which
seeks to rapidly translate innovations in science to improve
outcomes for patients with cancer, infectious diseases, autoimmune
and other acute and chronic disorders. He is an expert in drug
discovery and drug-resistance mechanisms, and has helped develop
novel therapeutics and diagnostics against high-threat bacteria,
viruses and fungi. He has published more than 320 papers and book
chapters, and has co-authored two books. The National Institutes of
Health (NIH) has continuously funded his research for more than 30
years.
Dr. Perlin has served on advisory boards for the
NIH, Bill & Melinda Gates Foundation, Global Action Fund for
Fungal Infections, Aaron Diamond AIDS Research Center and numerous
pharma, biotech and diagnostic companies. He is a Fellow of the
American Academy of Microbiology (2018) and the New York Academy of
Sciences (2006). In 2022, he was named a top 25 Notable Health Care
Leader by Crain’s New York Business and in 2023 was awarded the Dr.
Sol J. Barer Award for Vision, Innovation and Leadership.
About MAT2203Matinas BioPharma
is developing MAT2203 as a potential oral broad-spectrum treatment
for invasive deadly fungal infections. Although amphotericin B is a
fungicidal agent, it is currently only available through an
intravenous route of administration, which is known to be
associated with several significant safety issues such as renal
toxicity and anemia due to very high circulating levels of
amphotericin B. MAT2203 has the potential to overcome the
significant limitations of the currently available amphotericin B
products due to its targeted oral delivery. Combining comparable
fungicidal activity with targeted delivery results in a lower risk
of toxicity and potentially creates the ideal antifungal agent for
the treatment of invasive fungal infections. MAT2203 was
successfully evaluated in the completed Phase 2 EnACT study in HIV
patients suffering from cryptococcal meningitis, meeting its
primary endpoint and achieving robust survival. MAT2203 will be
further evaluated in a single Phase 3 registration trial (the
“ORALTO” trial) as an oral step-down monotherapy following
treatment with AmBisome (liposomal amphotericin B) compared with
the standard of care in patients with invasive aspergillosis who
have limited treatment options.
About Matinas BioPharmaMatinas
BioPharma is a biopharmaceutical company focused on delivering
groundbreaking therapies using its lipid nanocrystal (LNC) platform
delivery technology.
In addition to MAT2203, preclinical and clinical
data have demonstrated that this novel technology can potentially
provide solutions to many challenges of achieving safe and
effective intracellular delivery of both small molecules and
larger, more complex molecular cargos including small
oligonucleotides such as ASOs and siRNA. The combination of its
unique mechanism of action and flexibility with routes of
administration (including oral) positions Matinas’ LNC technology
to potentially become a preferred next-generation orally available
intracellular drug delivery platform. For more information, please
visit www.matinasbiopharma.com.
Forward-looking StatementsThis
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including
those relating to our business activities, our strategy and plans,
the future development of our product candidates, including
MAT2203, the Company’s ability to identify and pursue development,
licensing and partnership opportunities for our products, including
MAT2203, or platform delivery technology on favorable terms, if at
all, and the ability to obtain required regulatory approval and
other statements that are predictive in nature, that depend upon or
refer to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to continue as a going concern, our ability to obtain additional
capital to meet our liquidity needs on acceptable terms, or at all,
including the additional capital which will be necessary to
complete the clinical trials of our product candidates; our ability
to successfully complete research and further development and
commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor ContactLHA Investor
RelationsJody Cain Jcain@lhai.com310-691-7100
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2023 to Aug 2024